Skip to content

Identification of Infections in Hip Arthroplasty Loosening.

Application of Advanced High-sensitivity Technologies for Identifying Infections in Patients With Aseptic Loosening of Hip Arthroplasty.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04773054
Enrollment
11
Registered
2021-02-26
Start date
2022-02-08
Completion date
2024-02-15
Last updated
2024-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Loosening, Prosthesis

Keywords

Hip arthroplasty, Infection, Microbiota, Next Generation Sequencing

Brief summary

Recent data showed that the rate of periprosthetic infections in patients undergoing a hip arthroplasty revision for aseptic loosening is higher than what can be ascertained with conventional methods. The study aims to assess the adequacy of next-generation sequencing of 16s ribosomal ribonucleic acid (rRNA) gene amplicons for identifying occult infections and improving the diagnostic workup. Moreover, additional testing has been planned in order to increase knowledge on the etiopathogenesis of infection.

Detailed description

Periprosthetic infection following hip arthroplasty is one of the main causes of implant failure that leads to multiple surgical interventions, prolonged hospitalization, and higher complication rate and mortality. Recent data prove that the rate of periprosthetic infections is higher than what can be ascertained with conventional techniques and highlight as analytical methods that allow an early and accurate diagnosis may help clinicians identify effective treatment and mitigate the devastating consequences. New technologies based on culture-independent assays, i.e., the next-generation sequencing (NGS) of 16s rRNA gene amplicons, have entered medical microbiology as an alternative to traditional bacterial identification methods. NGS has been proven to detect microorganisms in culture-negative periprosthetic joint infection and seems to be a valid adjunct in identifying causative pathogens in samples from patients undergoing a hip arthroplasty revision for aseptic loosening. The microbiota profiling using NGS may also help identify patients prone to develop infections. In predisposing clinical conditions, i.e., obesity and diabetes, the metabolic and nutritional alterations modify the composition and the immunomodulatory properties of intestinal microbiota. Saprophytic, non-pathogenic microorganisms usually found in the intestine and oral cavity can be transferred to other areas becoming a potential source of periprosthetic infection. Additionally, microorganisms may live in the periprosthetic microenvironment without giving signs of overt infection. However, bacterial products, i.e., microbe-associated molecular patterns (MAMPs) or pathogen-associated molecular patterns (PAMPs), adhere to the implant surface or the wear particles and may elicit a local inflammatory response characterized by the presence of cells capable of producing cytokines that promote osteoclastogenesis, periprosthetic resorption and consequent loosening of the implant. In summary, the current knowledge suggests that the hip arthroplasty loosening, classified as aseptic according to the preoperative clinical and laboratory investigations, could be directly or indirectly associated with infectious pathogenesis even if the microbial cultures on periprosthetic tissues are negative. The investigators designed a small-scale study to assess the adequacy of NGS for identifying occult infections and improving the diagnostic workup in patients undergoing a hip arthroplasty revision for aseptic loosening. Moreover, additional testing has been planned to enhance knowledge on the role of unusual or difficult-to-cultivate microorganisms in the etiopathogenesis of implant failure.

Interventions

DIAGNOSTIC_TESTMicrobiological analysis of periprosthetic tissue

Microbiological culture of tissue samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.

DIAGNOSTIC_TESTHistological analysis of periprosthetic tissue

Histological assessment of cellular reactivity associated with the infection on tissue samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.

OTHERCharacterization of tissue microbiota

Assessment of tissue microbiome composition using the next-generation sequencing of DNA extracted from samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.

OTHERCharacterization of gut microbiota

Assessment of gut microbiome composition using the next-generation sequencing of DNA extracted from stool samples.

OTHERCharacterization of oral microbiota

Assessment of oral microbiome composition using the next-generation sequencing of DNA extracted from a buccal swab obtained by rubbing the mucosa of cheeks, gingivae, and palate.

Sponsors

Istituto Ortopedico Rizzoli
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Hip arthroplasty revision for aseptic loosening, diagnosis determined as probable according to the following criteria: * pain and/or functional impairment; * radiographic signs of osteolysis following wear of the implant components, or cortical reaction, or periprosthetic bone resorption; * negative evaluation by the infectious disease specialist.

Exclusion criteria

* presence of a sinus tract communicating with the arthroplasty; * bacteria isolation from aspirates or blood cultures performed preoperatively; * serum C-reactive protein higher than 10 mg/L; * recurrent implant dislocations; * prosthetic fracture; * medical history for septic arthritis, osteomyelitis; * infections in anatomic areas other than hip; * antibiotic therapy in the 15 days prior to surgery (with the exception of preoperative antibiotic prophylaxis); * chronic treatment with immunosuppressive drugs; * medical contraindications for executing sample collection.

Design outcomes

Primary

MeasureTime frameDescription
Identification of microorganisms by microbiological cultures (number of patients with positive microbiological culture).Within two week of admissionTissue samples will be sent for microbiological cultures and treated for the isolation of aerobic and anaerobic pathogens. The existence of two positive cultures will be considered to be diagnostic for periprosthetic infection; a single positive culture may occur from a contaminating organism and will be considered in conjunction with other markers of infection, including histological features.
Number of patients with histological features of periprosthetic infectionWithin two week of admissionThe presence of a periprosthetic infection will be established according to the number of polymorphonuclear cells (PMN) counted in ten high-power fields (HPF) (400 × magnification, field diameter 0.54 mm)- Uninfected: 0-5 PMNs in 10 HPFs; borderline, but probably not infected: 6-10 PMNs for 10 HPF; borderline, but probably infected: \>10 PMNs for 10 HPFs (but not \> 5 PMNs in a single HPF); infected \> 5 for HPF.
Identification of microorganisms by next-generation sequencing (NGS) (number of patients with positive NGS).Through study completion, an average of 6 months.The NGS will be employed to characterize the overall microbiome profile in tissue samples, and bioinformatics used to determine the taxonomic and phylogenetic affiliation, alpha-diversity (ecological diversity of a single sample according to the number of different taxa and their relative abundances), and beta-diversity (differences in microbial community composition between samples).

Secondary

MeasureTime frameDescription
Characterization of alpha-diversity and beta-diversity of oral microbiotaThrough study completion, an average of 6 months.The NGS technology will be employed to characterize the overall microbiome profile in oral swab, and bioinformatics used to determine alpha-diversity (ecological diversity of a single sample according to the number of different taxa and their relative abundances) and beta-diversity (differences in microbial community composition between samples
Characterization of taxonomic and phylogenetic affiliation of gut microbiotaThrough study completion, an average of 6 months.The NGS technology will be employed to characterize the overall microbiome profile in stool samples, and bioinformatics used to determine the taxonomic and phylogenetic affiliation.
Number of patients with inflammatory cellular reactivity related to bacterial products.Through study completion, an average of 6 months.The inflammatory cellular reactivity proved by the presence of activated macrophages and Toll-like-receptor positive cells.
Characterization of alpha-diversity and beta-diversity of gut microbiotaThrough study completion, an average of 6 months.The NGS technology will be employed to characterize the overall microbiome profile in stool samples, and bioinformatics used to determine alpha-diversity (ecological diversity of a single sample according to the number of different taxa and their relative abundances) and beta-diversity (differences in microbial community composition between samples).
Characterization of taxonomic and phylogenetic affiliation of oral microbiotaThrough study completion, an average of 6 months.The NGS technology will be employed to characterize the overall microbiome profile in oral swab, and bioinformatics used to determine the taxonomic and phylogenetic affiliation.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026